Proteomic analysis of terminalia chebula extract-dependent changes in human lymphoblastic T cell protein expression

Journal of Medicinal Food

Volumn 15, Issue 7, 2012, Pages 651-657

  Das, Nando Dulal ^a   Jung, Kyoung Hwa ^a   Park, Ji Hyun ^a   Choi, Mi Ran ^a   Lee, Hyung Tae ^a   Kim, Moo Sung ^b   Lee, Sang Rin ^b   Chai, Young Gyu ^a  

^a Hanyang University   (South Korea)

^b MacroCare Company   (South Korea)

Author keywords

gallic acid; Ingenuity Pathways Analysis; Jurkat cells; nuclear factor jB; Terminalia chebula extract

Indexed keywords

BETA TUBULIN; CHY ZINC FINGER DOMAIN CONTAINING 1; GALLIC ACID; INSULIN RECEPTOR KINASE; RING FINGER PROTEIN; TERMINALIA CHEBULA EXTRACT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DOWN REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; ZINC FINGER MOTIF;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; JURKAT CELLS; LEUKEMIA, T-CELL; NF-KAPPA B; PHOSPHOTRANSFERASES; PHYTOTHERAPY; PLANT EXTRACTS; PROTEOME; PROTEOMICS; RECEPTOR, IGF TYPE 1; T-LYMPHOCYTES; TERMINALIA; TUBULIN; ZINC FINGERS;

TERMINALIA CHEBULA;

EID: 84864075088     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2011.1998     Document Type: Article

References (25)

1. Fabry W, Okemo PO, Ansorg R: Antibacterial activity of East African medicinal plants. J Ethnopharmacol 1998;60:79-84.
2. Sabu MC, Kuttan R: Anti-Diabetic activity of medicinal plants and its relationship with their antioxidant property. J Ethnopharmacol 2002;81:155-160.
3. Saleem A, Husheem M, Harkonen P, Pihlaja K: Inhibition of cancer cell growth by crude extract and the phenolics of Terminalia chebula Retz. fruit. J Ethnopharmacol 2002;81:327-336.
4. Reddy DB, Reddy TC, Jyotsna G, et al.: Chebulagic acid, a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz., induces apoptosis in COLO-205 cell line. J Ethnopharmacol 2009;124:506-512.
5. Abraham RT, Weiss A: Jurkat T cells and development of the Tcell receptor signalling paradigm. Nat Rev Immunol 2004;4:301-308.
6. Das ND, Jung KH, Park JH, et al.: Terminalia chebula extract acts as a potential NF-kappaB inhibitor in human lymphoblastic T cells. Phytother Res 2011;25:927-934.
7. Bharti AC, Donato N, Singh S, Aggarwal BB: Curcumin (diferuloylmethane) down-Regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003;101:1053-1062.
8. Arur S, Uche UE, Rezaul K, et al.: Annexin I is an endogenous ligand that mediates apoptotic cell engulfment. Dev Cell 2003;4:587-598.
9. Wang P, Song JH, Song DK, Zhang J, Hao C: Role of death receptor and mitochondrial pathways in conventional chemotherapy drug induction of apoptosis. Cell Signal 2006;18:1528-1535.
10. Das ND, Park JH, Jung KH, et al.: Sodium arsenite dependent protein expression analysis on human embryonic carcinoma (NCCIT) cell line. Toxicol Lett 2011;207:149-158.
11. Shevchenko A, Wilm M, vorm O, Mann M: Mass spectrometric sequencing of proteins silver-Stained polyacrylamide gels. Anal Chem 1996;68:850-858.
12. Li CJ, Li RW, Wang YH, Elsasser TH: Pathway analysis identifies perturbation of genetic networks induced by butyrate in a bovine kidney epithelial cell line. Funct Integr Genomics 2007;7:193-205.
13. Tsai J, Zhang R, Qiu W, Su Q, Naples M, Adeli K: Inflammatory NF-kappaB activation promotes hepatic apolipoprotein B100 secretion: Evidence for a link between hepatic inflammation and lipoprotein production. Am J Physiol Gastrointest Liver Physiol 2009;296:G1287-G1298.
14. Leng RP, Lin Y, Ma W, et al.: Pirh2, a p53-Induced ubiquitinprotein ligase, promotes p53 degradation. Cell 2003;112:779-791.
15. Duan W, Gao L, Wu X, Zhang Y, Otterson GA, villalona-Calero MA: Differential response between the p53 ubiquitin-Protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells. Exp Cell Res 2006;312:3370-3378.
16. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr: Molecular and cellular aspects of the insulin-Like growth factor I receptor. Endocr Rev 1995;16:143-163.
17. Jones HE, Goddard L, Gee JM, et al.: Insulin-Like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004;11:793-814.
18. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay vM: Expression of the type 1 insulin-Like growth factor receptor is up-Regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002;62:2942-2950.
19. Fukui Y, Hashimoto O, Sanui T, et al.: Haematopoietic cellspecific CDM family protein DOCK2 is essential for lymphocyte migration. Nature 2001;412:826-831.
20. Wysocka J, Swigut T, Milne TA, et al.: WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. Cell 2005;121:859-872.
21. Shin BK, Wang H, Yim AM, et al.: Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem 2003;278:7607-7616.
22. Asea A, Kraeft SK, Kurt-Jones EA, et al.: HSP70 stimulates cytokine production through a CD14-Dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000;6:435-442.
23. Triantafilou K, Triantafilou M, Dedrick RL: A CD14-Independent LPS receptor cluster. Nat Immunol 2001;2:338-345.
24. Hantschel M, Pfister K, Jordan A, et al.: Hsp70 plasma membrane expression on primary tumor biopsy material and bone marrow of leukemic patients. Cell Stress Chaperones 2000;5;438-42.
25. Reddy DB, Reddanna P: Chebulagic acid (CA) attenuates LPSinduced inflammation by suppressing NF-kappaB and MAPK activation in RAW 264.7 macrophages. Biochem Biophys Res Commun 2009;381:112-117.